Michael J. Morris, MD

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the rationale behind TAX 3503 (hormonal therapy +/- docetaxel for patients at high risk of metastatic prostate cancer).

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of biomarkers in prostate cancer clinical trials.

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.